Pressemitteilung vom 11.05.2020 Nachricht vom 11.05.2020


Signale (in Diskussion) Mai 2020

11-14 May 2020

  • Andexanet alfa – ONDEXXYA (CAP)
  • Baricitinib - OLUMIANT (CAP)
  • Buprenorphine – BUVIDAL (CAP), SIXMO (CAP), NAP; buprenorphine, naloxone – SUBOXONE (CAP), ZUBSOLV (CAP), NAP;Selective serotonin reuptake inhibitors (SSRIs): citalopram (NAP); escitalopram (NAP); fluvoxamine (NAP); fluoxetine (NAP); paroxetine (NAP); sertraline (NAP);Serotonin norepinephrine reuptake inhibitors (SNRIs): desvenlafaxine (NAP); duloxetine – CYMBALTA (CAP), DULOXETINE LILLY (CAP), DULOXETINE MYLAN (CAP), DULOXETINE ZENTIVA (CAP), XERISTAR (CAP), YENTREVE (CAP), NAP; milnacipran (NAP); venlafaxine (NAP);Tricyclic antidepressants (TCAs): amitriptyline (NAP); clomipramine (NAP); doxepin (NAP); imipramine (NAP); nortriptyline (NAP); trimipramine (NAP); Monoamine oxidase inhibitors (MAOIs): isocarboxazid (NAP); phenelzine (NAP); selegiline (NAP); tranylcypromine (NAP);Other psychiatric medicines: amoxapine (NAP); buspirone (NAP); lithium (NAP); maprotiline (NAP); mirtazapine (NAP); trazodone (NAP);Serotonin receptor agonists: almotriptan (NAP); frovatriptan (NAP); naratriptan(NAP); rizatriptan (NAP); sumatriptan (NAP); zolmitriptan (NAP); Antiemetics: granisetron - SANCUSO (CAP), NAP; ondansetron (NAP); palonosetron – ALOXI (CAP), PALONOSETRON ACCORD (CAP), NAP; netupitant, palonosetron – AKYNZEO (CAP); tropisetron (NAP);Other serotonergic drugs: cyclobenzaprine (NAP); dextromethorphan (NAP); hypericum perforatum (NAP); linezolid (NAP); methylene blue (NAP); tryptophan (NAP)
  • Cobicistat - TYBOST (CAP)
  • Dabrafenib – TAFINLAR (CAP); t rametinib – MEKINIST(CAP)
  • Dipeptidyl peptidase-4 (DPP4) inhibitors: alogliptin - VIPIDIA (CAP); alogliptin, metformin hydrochloride - VIPDOMET (CAP); alogliptin, pioglitazone - INCRESYNC (CAP); linagliptin - TRAJENTA (CAP); saxagliptin - ONGLYZA (CAP); saxagliptin, dapagliflozin - QTERN (CAP); s axagliptin, metformin hydrochloride - KOMBOGLYZE (CAP); sitagliptin – JANUVIA (CAP), RISTABEN (CAP); TESAVEL (CAP), XELEVIA (CAP); NAP; sitagliptin, ertugliflozin – STEGLUJAN (CAP); sitagliptin, metformin – EFFICIB (CAP); JANUMET (CAP); VELMETIA (CAP);NAP; vildagliptin - GALVUS (CAP), JALRA (CAP), XILIARX (CAP); vildagliptin, metformin hydrochloride - EUCREAS (CAP), ICANDRA (CAP), ZOMARIST (CAP); NAP
  • Dipeptidyl peptidase-4 (DPP4) inhibitors: alogliptin - VIPIDIA (CAP) ; alogliptin, metformin hydrochloride - VIPDOMET (CAP) ; alogliptin, pioglitazone - INCRESYNC (CAP); linagliptin - TRAJENTA (CAP); saxagliptin - ONGLYZA (CAP) ; saxagliptin, dapagliflozin - QTERN (CAP); s axagliptin, metformin hydrochloride - KOMBOGLYZE (CAP); sitagliptin – JANUVIA (CAP), RISTABEN (CAP), TESAVEL (CAP), XELEVIA (CAP); NAP; sitagliptin, ertugliflozin – STEGLUJAN (CAP); sitagliptin, metformin – EFFICIB (CAP); JANUMET (CAP); VELMETIA (CAP);NAP; vildagliptin - GALVUS (CAP), JALRA (CAP) , XILIARX (CAP); vildagliptin, metformin hydrochloride - EUCREAS (CAP), ICANDRA (CAP), ZOMARIST (CAP) ; NAP
  • Fluoroquinolones: ciprofloxacin (NAP); delafloxacin – QUOFENIX (CAP); levofloxacin – QUINSAIR (CAP), NAP; lomefloxacin (NAP); moxifloxacin (NAP); norfloxacin (NAP); ofloxacin (NAP); pefloxacin (NAP); prulifloxacin (NAP); rufloxacin (NAP)
  • Hormone replacement therapy (HRT):chlorotrianisene (NAP); conjugated estrogens (NAP); conjugated estrogens, bazedoxifene - DUAVIVE (CAP) - EMEA/H/C002314/SDA 005; dienestrol (NAP); diethylstilbestrol (NAP); estradiol (NAP); estradiol, norethisterone (NAP); estriol (NAP); estrone (NAP); ethinylestradiol (NAP); methallenestril (NAP); moxestrol (NAP); promestriene (NAP); tibolone (NAP)
  • Mirtazapine (NAP)
  • Olaparib - LYNPARZA (CAP)
  • Pembrolizumab – KEYTRUDA (CAP)
  • Sertraline (NAP)
Zurück zur Übersicht

Rechtliche Hinweise

Der BPI Wirkstoff-Alert wird mit größter Sorgfalt zusammengestellt.
Der BPI e.V. haftet jedoch nicht für Unrichtigkeiten oder Unvollständigkeiten im Zusammenhang mit den bereitgestellten Inhalten. Dies gilt im Besonderen auch für eigene unternehmerische Entscheidungen, die auf Grundlage der Informationen des BPI Wirkstoff-Alerts getroffen werden.